🔎 Trials Near Me

Beranda › Leukemia Limfoblastik Akut › Illinois › Chicago

Uji klinis Leukemia Limfoblastik Akut di Chicago, IL

19 studi untuk Leukemia Limfoblastik Akut mencari peserta di lokasi sekitar Chicago (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • dan 1 lainnya
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Menerima pesertaFase 1/2
  • The University of Chicago Medical Center, Chicago
30 Days · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04065399

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Menerima pesertaFase 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Menerima pesertaFase 2
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Usia 7 hingga 25 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05082519

A Study of CTD402 in T-ALL/LBL Patients

Menerima pesertaFase 1/2
  • University of Chicago, Chicago
Usia 1 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07070219

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Menerima pesertaStudi observasional
  • The University of Chicago, Chicago
1 Day – 17 Years · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT06274788

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Menerima pesertaFase 1/2
  • Research Site, Chicago
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT07109219

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Menerima peserta
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT06446661

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Menerima pesertaStudi observasional
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • dan 2 lainnya
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Menerima peserta
  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
Usia 14 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT03932903

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Menerima pesertaFase 1
  • University of Chicago Medical Center, Chicago
Usia 18 hingga 39 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT03571321

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Menerima pesertaFase 2
  • University of Chicago Medical Center, Chicago
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Jun 2026 · NCT04747912

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Menerima pesertaStudi observasional
  • Lurie Children's Hospital-Chicago, Chicago
Semua usia · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT01790152

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Menerima pesertaFase 1
  • University of Chicago, Chicago
Usia 13 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT04771572

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Menerima pesertaFase 1/2
  • Northwestern, Chicago
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 24 Mar 2026 · NCT04988555

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Menerima pesertaFase 1/2
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mar 2026 · NCT06207123

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Menerima pesertaFase 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Usia 18 hingga 54 · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06918431

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Menerima pesertaFase 1
  • Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Usia 1 hingga 40 · Semua jenis kelamin · Diperbarui 12 Mar 2026 · NCT05292664

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Menerima pesertaFase 1
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770

Uji klinis Leukemia Limfoblastik Akut di kota lain

Studi lain di Chicago

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.